LY3022855 clinical trials
Also written LY3022855.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses LY3022855 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Eli Lilly and Company (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Dana-Farber Cancer Institute (1)
Studies
Open first, then newest update. How each study uses LY3022855 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the PancreasCompletedEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03153410Written as IMC-CS4
- A Study of LY3022855 In Participants With Breast or Prostate CancerCompletedPhase 1Eli Lilly and CompanyNCT02265536Written as LY3022855
- A Study of IMC-CS4 in Subjects With Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT01346358Written as IMC-CS4
- LY3022855 With BRAF/MEK Inhibition in Patients With MelanomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT03101254Written as LY3022855